25th week of 2017 patent applcation highlights part 12 |
Patent application number | Title | Published |
20170173153 | PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST CANDIDIASIS | 2017-06-22 |
20170173154 | MULTI-DRUG DELIVERY SYSTEM AND USE THEREOF - Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided. | 2017-06-22 |
20170173155 | GLUTAMINE-HIGH Z ELEMENT COMPOUNDS FOR TREATING CANCER - The present invention is a glutamine compound having a non-radioisotope high Z element attached via a linker, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction. | 2017-06-22 |
20170173156 | Compositions - The invention provides a colon cleansing solution comprising: | 2017-06-22 |
20170173157 | METHOD OF MANUFACTURING FINE PARTICLES SUITABLE FOR ORALLY DISINTEGRATING PHARMACEUTICAL DOSAGE FORMS - Disclosed are methods of making oral pharmaceutical compositions that contain substantially crush resistant drug containing microparticles. The microparticles may contain an active pharmaceutical agent, a polymer and a plasticizer. The microparticles may be un-coated (so as to impart an immediate release profile) or coated so as to impart an extended release (ER), delayed release (DR) or delayed extended release (DER) profile. One or more of the populations of microparticles may be coated with a taste masking composition. The methods may produce oral compositions such as orally disintegrating tablets that contain one or more these types of microparticles in order to further customize the release profile. Also disclosed are the oral compositions, per se, and methods of using same for their intended purposes. | 2017-06-22 |
20170173158 | Use of a Polyanionic Composition - Disclosed herein is a use of a composition, comprising a non-toxic polyanionic material or a salt thereof to dissociate a polymeric membrane. In addition, a method of dissociating a polymeric membrane is also presented, the method comprising the steps of providing a polymeric membrane; and dissociating the polymeric membrane by adding a composition comprising a non-toxic polyanionic material to the polymeric membrane. | 2017-06-22 |
20170173159 | DISPERSION COMPRISING AN ESTERIFIED CELLULOSE ETHER - An aqueous composition useful for producing capsules shells comprises a) at least one dispersed esterified cellulose ether comprising (i) groups of the formula —C(O)—R—COOA or (ii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, and b) from 0.05 to 20 percent of at least one salt of a fatty acid, based on the weight of the dispersed esterified cellulose ether, wherein the median particle size, d50, of the dispersed esterified cellulose ether particles is up to 7 micrometers, such median particle size (d50) being the size at which 50 mass percent of the particles have a smaller equivalent diameter and 50 mass percent have a larger equivalent diameter. | 2017-06-22 |
20170173160 | COMPOSITION FOR FORMING A FILM - Provided is a composition for forming a film, the composition not having completely dissolved hydroxypropyl methyl cellulose (HPMC), and enabling formation of the film having a uniform thickness by suppressing the viscosity increase of the composition around an immersion temperature of 50° C. More specifically provided is a composition for forming a film, the composition comprising hypromellose having methoxy group content of 28.0 to 30.0% by weight and hydroxypropoxy group content of 7.6 to 8.5% by weight, wherein a 2% by weight aqueous solution of the hypromellose provides a viscosity at 20° C. of 4.0 to 6.5 mPa·s, a 20% by weight dispersion of the hypromellose provides a viscosity at 50° C. of 2,000 to 11,000 mPa·s, and a 20% by weight aqueous solution of the hypromellose provides a gelation temperature of 54 to 57° C.; and a solvent. | 2017-06-22 |
20170173161 | COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT - Embodiments of various aspects described herein are directed to silk-based compositions for ocular delivery of at least one active agent, e.g., at least one therapeutic agent and methods of using the same. In some embodiments, the silk-based compositions can provide sustained release of at least one therapeutic agent to at least a portion of an eye. Thus, some embodiments of the silk-based compositions can be used for treatment of an ocular condition, e.g., age-related macular degeneration. | 2017-06-22 |
20170173162 | Natural Preservatives and Antimicrobial Agents, Including Compositions Thereof - Compositions are disclosed herein that comprise a mixture of at least one | 2017-06-22 |
20170173163 | CONJUGATE OF A FRAGMENT OF A CELLULAR WALL OF A BACTERIUM AND A MUCOPOLYSACCHARIDIC CARRIER, AND USES IN MEDICINE THEREOF - The present invention relates in one aspect to a conjugate of a mucopolysaccharide or mucopolysaccharidic fraction and a cellular wall fragment of a bacterium belonging to the | 2017-06-22 |
20170173164 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM - 1H-Imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed. | 2017-06-22 |
20170173165 | BACTERIAL PHOSPHOLIPASE INHIBITORS AS MODULATOR OF COLONIC BACTERIAL FLORA - The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine. In particular, it relates to diseases that are associated with bacterial invasion of the intestinal mucus, including, inflammatory bowel diseases, and infectious bacterial diseases. Therefore, the present invention provides agents, a pharmaceutical composition and a kit for treating said diseases. It further relates to a use and a method for treating invasive bacterial diseases of the large intestine. | 2017-06-22 |
20170173166 | GLYCEROPHOSPHOLIPIDS FOR THE IMPROVEMENT OF COGNITIVE FUNCTIONS - The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations. | 2017-06-22 |
20170173167 | Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments - The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4/D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent. | 2017-06-22 |
20170173168 | ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE - Cell binding agent-drug conjugates comprising bridge linkers, and methods of using such linkers and conjugates are provided. | 2017-06-22 |
20170173169 | CROSS-LINKED POLYMER MODIFIED NANOPARTICLES - Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease. | 2017-06-22 |
20170173170 | METHODS AND MATERIALS FOR THERAPEUTIC DELIVERY - Method for preparing a supramolecular therapeutic agent delivery assembly are provided. A carbonate-containing precursor, a functionalized aliphatic precursor, and an aromatic diamine precursor may be combined to form an amphiphilic block co-polymer. The block co-polymer undergo a cross-linking polymerization process and a therapeutic agent may be incorporated into the resulting supramolecular assembly. The supramolecular assembly may comprise HT, PHT, HA, and/or PHA materials. | 2017-06-22 |
20170173171 | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same - The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative. | 2017-06-22 |
20170173172 | SELECTIVE DENDRIMER DELIVERY TO BRAIN TUMORS - A composition comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier (“BBB”) of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation. | 2017-06-22 |
20170173173 | Skin Permeating and Cell Entering (SPACE) Peptides and Methods of Use Thereof - The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells. | 2017-06-22 |
20170173174 | BLADDER CANCER SPECIFIC LIGAND PEPTIDES - The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X | 2017-06-22 |
20170173175 | SITE-SPECIFIC ANTIBODY-DRUG GLYCOCONJUGATES AND METHODS - Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof. | 2017-06-22 |
20170173176 | ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE - Cell binding agent-drug conjugates comprising bridge linkers, and methods of using such linkers and conjugates are provided. | 2017-06-22 |
20170173177 | Tubular Nanostructure Targeted To Cell Membrane - Devices, compositions, and methods are described which provide a tubular nanostructure or a composite tubular nanostructure targeted to a lipid bilayer membrane. The tubular nanostructure includes a hydrophobic surface region flanked by two hydrophilic surface regions. The tubular nanostructure is configured to interact with a lipid bilayer membrane and form a pore in the lipid bilayer membrane. The tubular nanostructure may be targeted by including at least one ligand configured to bind to one or more cognates on the lipid bilayer membrane of a target cell. | 2017-06-22 |
20170173178 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. | 2017-06-22 |
20170173179 | PREVENTION OF ESCHERICHIA COLI DIARRHEA - The present invention provides an agent for controlling | 2017-06-22 |
20170173180 | CANCER IMMUNOTHERAPY COMPOSITIONS AND METHODS - The present invention relates to compositions and methods for cancer immunotherapy. In particular, the present invention relates to engineered effector B cells and their use in cancer immunotherapy. | 2017-06-22 |
20170173181 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS - The present disclosure is directed to adeno-associated viral vector monoclonal antibody constructs and compositions thereof, methods of improving locomotor function after spinal cord injury, methods of treating neurodegenerative diseases. | 2017-06-22 |
20170173182 | COMPOSITION FOR mRNA DELIVERY - A polyion complex of mRNA and a polycationic polymer, and a composition and a pharmaceutical composition for mRNA delivery are provided. The polyion complex of mRNA and the polycationic polymer can deliver mRNA into cells in the body of a subject almost without inducing inflammation. The polyion complex can then cause mRNA to be uniformly expressed in cells in the body of the subject. The pharmaceutical composition containing the polyion complex is suitable for use in treating a disease whose condition rapidly progresses or an acute disease. | 2017-06-22 |
20170173183 | GENE THERAPY FOR RETINITIS PIGMENTOSA - Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated. | 2017-06-22 |
20170173184 | TREATMENT - The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient. | 2017-06-22 |
20170173185 | GLOBIN GENE THERAPY FOR TREATING HEMOGLOBINOPATHIES - The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject. | 2017-06-22 |
20170173186 | MURINE WOUND MODEL FOR TESTING PATHOGEN VIRUENCE AND THERAPEUTIC EFFICACY - The invention provides a murine model of wound infection and biofilm formation and methods for producing such model. The inventive murine model of wound infection may be used to evaluate pathogen virulence and test efficacy of a pharmaceutical composition and/or a treatment procedures in preventing or treating wound infection, reducing biofilm formation, or reducing symptoms in a subject. | 2017-06-22 |
20170173187 | PRUSSIAN BLUE-INSPIRED CONSTRUCTS FOR MULTIMODAL IMAGING AND THERAPY - The invention describes a coordination polymer construct for multimodal imaging and therapy. The construct consists of a core particle made of a novel coordination polymer. The core is coated with a biocompatible coating that stabilizes the particles in a physiological environment. The biocompatible coating can contain attached targeting agents, imaging agents and therapeutic agents or combinations one or more of the targeting, imaging and therapeutic agents. When administered to a subject or a subject-derived specimen, the resulting coordination polymer core-shell construct enables multimodal imaging and therapy, which improves the diagnostic and treatment outcomes of the conditions or diseases where it is administered. The invention describes the novel material, base for the construct, methods for the preparation of the said construct and its use as a multimodal imaging and therapy agent. | 2017-06-22 |
20170173188 | MEASUREMENT OF BODY FLUID VOLUMES - The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV−TVPV. | 2017-06-22 |
20170173189 | PALATABLE LIQUID DILUTION VEHICLES FOR ORAL CONTRAST AGENTS - The invention relates to liquid vehicles that can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability. | 2017-06-22 |
20170173190 | GADOLINIUM EXPRESSED LIPID NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING - Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging. | 2017-06-22 |
20170173191 | Method to Visualize Very Early Stage Neoplasm or Other Lesions - A method for evaluating treatment outcome in a patient having a genetic predisposition for a malignant neoplasm before clinical manifestation of the neoplasm can be seen radiographically. The method permits visualization of any tumor, whether located externally on a patient's body or located internally in the body, and as small as 2 mm in diameter, using a biomarker. The method uses biomarkers conjugated with nanoparticles which include but are not limited to quantum dots, with the conjugated form collectively termed functionalized nanoparticles, that are heated under specified conditions to produce a photoacoustic signal that is then visualized to locate and/or treat the tumor. | 2017-06-22 |
20170173192 | METHOD FOR STERILIZATION OF AQUEOUS POLYSACCHARIDE SOLUTIONS AND STERILE AQUEOUS POLYSACCHARIDE SOLUTIONS - Sterilization method according to which an aqueous polysaccharide solution is stored in the presence of a lactone and a buffer system for a period of at least 24 hours, and a sterile polysaccharide solution produced in this way. | 2017-06-22 |
20170173193 | Sterilization Methods for Medical Devices - Methods of sterilizing medical devices, including implantable medical devices like stents, chemically and with radiation are disclosed. Methods of preparing a sterile, packaged medical device, including a sterile, packaged implantable medical device or stent are disclosed. | 2017-06-22 |
20170173194 | METAL MESH, STERILIZATION DETERMINATION METHOD, AND CLEANING DETERMINATION METHOD - A metal mesh has a plurality of through-holes. A photosensitive organic material is attached to at least part of the metal mesh. The metal mesh is sterilized and/or cleaned. A determination of whether or not the sterilization and/or cleaning has been successful is made by analyzing the photosensitive organic material attached to the metal mesh. | 2017-06-22 |
20170173195 | Room And Area Disinfection Utilizing Pulsed Light With Modulated Power Flux And Light Systems With Visible Light Compensation Between Pulses - Disinfection methods and apparatuses are provided which generate pulses of germicidal light at a frequency greater than 20 Hz and project the pulses of light to surfaces at least 1.0 meter from the disinfection apparatus. The pulses of light comprise a pulse duration and an energy flux sufficient to generate a power flux between approximately 200 W/m | 2017-06-22 |
20170173196 | COMPOSITIONS COMPRISING AN ESTER AND/OR AN ACID - The present disclosure relates to compositions comprising hydrogen peroxide in combination with C | 2017-06-22 |
20170173197 | DEVICES, SYSTEMS AND METHODS FOR ZONE STERILIZATION - A gas transfer system including a housing, a pressurized gas canister held by the housing, a first passageway in fluid communication with the pressurized gas canister and configured to supply pressurized pre-sterilization gas from the pressurized gas canister to a fluid flow component, a gas discharge canister held by the housing; and a second passageway in fluid communication with the gas discharge canister and configured to supply post-sterilization gas from the fluid flow component to the gas discharge canister. Additional related devices, systems and methods are provided. | 2017-06-22 |
20170173198 | ENVIRONMENTAL SANITIZER AND ODOR REMOVER FOR PURIFICATION OF FOODS, SURFACES, AIR AND WATER WITH DISPOSABLE OZONE GENERATION ELECTRODE, PRESSURE/FLOW ADAPTABLE VENTURI INJECTOR AND AQUEOUS PHASE FILTER DEVICE - A dielectric assembly for generating ozone includes a positive electrode, a negative electrode, a dielectric for generating the ozone, and a knob adapted to extend outside of a housing into which the dielectric assembly is to be placed. A system is also provided for sanitizing and deodorizing water, food, surfaces and air including a microbiological reduction filter device having an input connected to a water supply, a venturi injector disposed within a housing and connected to an output of the microbiological reduction filter device which generates ozone and mixes the generated ozone with the water, and an electrode assembly comprising a plurality of electrodes, a dielectric for generating the ozone, and a knob extending outside of the housing. The dielectric in a first embodiment and the entire dielectric assembly in a second embodiment can be removed from the housing and replaced in its entirety by the knob. | 2017-06-22 |
20170173199 | SYSTEM, METHOD AND PROCESS FOR DISINFECTION OF INTERNAL SURFACES IN ASEPTIC TANKS AND PIPELINES BY FLOODING WITH SANITIZING FOG - A system, method and process for disinfection of internal surfaces in aseptic tanks and pipelines by flooding with sanitizing fog in facilities designed to store liquids in general, the system having an external equipment with means to generate sanitizing fog, controlling means of gases flow rate, in-line detectors and draining means of gases inside the tank, input means of fog carrying means comprising inert gases. A disinfection process includes introduction of a sanitizing fog with droplets having a maximum size of 10 μm, and 5 μm in some embodiments, simultaneously with removal of gases enclosed inside the tanks and pipelines, maintaining a positive pressure inside the tanks and pipelines. The method providing reduction of oxygen concentration inside the tanks in two steps, the first step having reduction to near 10% and the second a reduction to a value below 1%, filling the tank with a sanitizing fog during the second step. | 2017-06-22 |
20170173200 | SANITATION PLATFORM - Implementations generally relate to a sanitizing platform. In one implementation, a system includes a base. The system also includes a first sanitizer mechanism coupled to the base, where the first sanitizer mechanism is configured to sanitize at least one hand of a user. The system also includes a second sanitizer mechanism coupled to the base, where the second sanitizer mechanism is configured to sanitize a door handle. | 2017-06-22 |
20170173201 | DEVICE FOR EVAPORATING VOLATILE SUBSTANCES - Device for evaporating volatile substances including a container for a liquid that contains volatile substances and means for evaporating the volatile substances, where the means for evaporating the volatile substances include two semipermeable membranes, such that the device allows the optimisation of the evaporation of the volatile substances present in the liquid, doubling the evaporation surface thereof compared to conventional devices, and increases the user's perception of the amount of liquid evaporated. | 2017-06-22 |
20170173202 | PUMP CONCENTRATED AIR FRESHENER - Non-pressurized pump dispensable concentrated air freshener compositions, and a method of freshening air using a pump article containing a concentrated air freshener composition, are described. The air freshener compositions have a reduced VOC content and provide a fragrance intensity and longevity having at least parity with conventional pressurized air freshening aerosols. | 2017-06-22 |
20170173203 | METHOD AND SYSTEM OF A NETWORKED SCENT DIFFUSION DEVICE - A diffusion device for atomizing liquids includes a floating magnet disposed within a track inside at least one package with liquid for the atomizing diffusion device, wherein as a liquid level inside the package changes, the floating magnet moves substantially vertically along the track, a plurality of Hall effect sensors or Hall effect switches disposed outside the liquid at various positions, the Hall effect sensors or Hall effect switches each generating an output voltage in response to a magnetic field of the floating magnet, and a processor that receives the output voltages and fits them to a model that includes the floating magnet position with respect to various sets of output voltages to determine a position of the floating magnet with respect to the Hall effect sensors. | 2017-06-22 |
20170173204 | Methods and Equipment for Treating Industrial Gas Streams and Biological Fouling - Methods for contacting removing an odorous or noxious component from a gas stream using a scrubbing solution containing a biocide in a gas/liquid contactor are described. The biocide is used to avoid or prevent or minimize or control biological growth and fouling, particularly in the gas/liquid contactor. | 2017-06-22 |
20170173205 | Systems and Methods for Fabricating an Air Purification Device - Systems and methods for fabricating an air purification device for use typically with heating, ventilating, and air conditioning (HVAC) system are presented. The systems include at least one pleated insert disposed within a cartridge housing and proximate a source of electromagnetic radiation. The pleated insert includes a plurality of pleat strips aligned substantially parallel to a common pleat axis. Each pleat strip has a first edge and a second edge. Portions or surfaces proximate the first edge and the second edge of each pleat strip are bonded so as to form an alternating sequence of peaks and valleys. A photocatalytic material coats at least a portion of the pleated insert. Methods for fabricating the pleated insert from a slice member having an unexpanded honeycomb structure are also presented. Other systems and methods are presented. | 2017-06-22 |
20170173206 | ELECTROCHEMICAL SYSTEM FOR DISINFECTING AND CLEANING CONTACT LENSES - The present invention is generally related to a lens care system and method for disinfecting and cleaning contact lenses. A lens care system or method of the invention is based on electrolysis of an aqueous chloride solution for generating germicide species (e.g., chlorine, hypochlorous acid, hypochlorite, or combinations thereof) and subsequent in-situ electrolysis of hypochlorous acid or hypochlorite in the aqueous solution for neutralizing the generated germicide species. | 2017-06-22 |
20170173207 | ABSORBENT PAD THAT INCLUDES A FATTY ACID COMPOSITION FOR ODOR CONTROL - An absorbent pad includes a batt of cellulose fibers, superabsorbent particles intermixed within the batt of cellulose fibers, and an odor control material intermixed within the batt of cellulose fibers, wherein the odor control material is a particulate material including one or more fatty acid. The odor control material preferably further includes selected inorganic compounds, such as sources of nitrogen, phosphorus and iron. Various embodiments incorporate the absorbent pad in a diaper or other disposable hygiene product. | 2017-06-22 |
20170173208 | ADHESIVE-CONTAINING WOUND CLOSURE DEVICE AND METHOD - An article, such as a tissue bonding article, includes a flexible material, a polymerization initiator or rate modifier disposed in or on the flexible material, and a polymerizable adhesive composition permeated throughout at least a portion of the flexible material, where the polymerization initiator or rate modifier is a polymerization initiator or rate modifier for the polymerizable adhesive composition. | 2017-06-22 |
20170173209 | WOUND CLOSURE COMPOSITIONS AND METHOD - A medical adhesive that bonds well to human tissue while curing in a fast, controllable mariner. In a preferred form, the medical adhesive includes an oligomer, a hydrogel and/or water soluble polymer and a photoinitiator. Preferred oligomers include epoxides, urethanes, polyethers, polyester or a combination thereof. Hydrogels and water soluble polymers aid adhesion to moist surfaces, such as skin tissue, because they are hydrophilic and biodegradable, Preferred hydrogels include polymer hydrogels (PHGs). Suitable water soluble polymers include polyethylene oxide) (PEO) and poly-2-oxazoline. The photoinitiator is used to obtain fast, controllable curing of the adhesive compound. Curing takes place on demand when ultraviolet (UV) light is applied to the medical adhesive. To increase adhesion as well as to control flexibility and toughness, the medical adhesive may also include one or more monomers. Suitable monomers include acrylates and vinyls. | 2017-06-22 |
20170173210 | ANTIBIOTIC POLYMETHYLMETHACRYLATE BONE CEMENT - The invention proposes an antibiotic polymethylmethacrylate bone cement that is composed of methylmethacrylate, at least one polymethylmethacrylate or a polymethylmethacrylate-copolymer, at least one polymerisation initiator, such as in radical initiator, at least one polymerisation accelerator, and at least one radiopaquer, whereby the components are present in a powdered component and a liquid monomer component or in two components that are pasty at room temperature. The polymethylmethacrylate bone cement according to the invention comprises the cyclical lipopeptide, daptomycin, a pharmacologically tolerable salt of daptomycin, a solvate and/or a hydrate containing daptomycin and at least one calcium salt, which preferably comprises at least two different release profiles. | 2017-06-22 |
20170173211 | METHOD OF PREPARING POROUS CARBONATE APATITE FROM NATURAL BONE - A carbonate apatite prepared from natural bone. The carbonate apatite has a protein content of 2000-8000 parts per million and a surface area of 15 to 70 m | 2017-06-22 |
20170173212 | COMPOSITIONS AND METHODS FOR GROWING AUTOLOGOUS BIOLOGICAL TISSUE - In one aspect, methods of growing autologous biological tissue are described herein. In some embodiments, a method described herein comprises disposing a porous scaffold in a body cavity of a patient, wherein the scaffold comprises one or more biofactors comprising one or more chemokines that promote migration of autologous multipotent cells into the body cavity and/or one or more differentiation agents that promote differentiation of autologous multipotent cells into the autologous biological tissue. The body cavity can comprise a soft tissue cavity such as the peritoneal cavity. A method described herein can also comprise depositing the multipotent cells onto a surface of the scaffold and inducing differentiation of the multipotent cells on the surface of the scaffold to provide differentiated autologous tissue. Additionally, a method can further comprise growing the autologous biological tissue from the differentiated autologous tissue. Further, the autologous tissue may not be native to the body cavity. | 2017-06-22 |
20170173213 | POLARIZED HYDROXYAPATITE FILMS AND METHODS OF MAKING AND USING SAME - Polarized hydroxyapatite films disposed on a substrate. The films have a residual polarization of at least 5 mC/cm2. Also provided are methods of making and using polarized hydroxyapatite. The films can be used as coatings of medical devices, such as, for example, medical implants. | 2017-06-22 |
20170173214 | METHODS FOR PREPARING DRY CROSS-LINKED TISSUE - A method of preparing dry cross-linked biological tissue. A processing solution is prepared that contains a cross-linking agent and an organic water-soluble liquid. Biological tissue is immersed in the processing solution for an effective period of time to substantially displace water from the biological tissue and substantially cross-link the biological tissue to form dry cross-linked biological tissue. | 2017-06-22 |
20170173215 | ENGINEERED CARDIAC DERIVED COMPOSITIONS AND METHODS OF USE - The present invention establishes a new standard for investigative studies of patient-specific, genetic cardiac diseases at a functional, tissue level by creating a novel platform for the study of cardiac related diseases, including cardiac conduction dysfunction, arrhythmias and depressed contractility for example. Provided herein are novel compositions of human engineered heart slices (EHS) formed from thin slices of decellularized cardiac tissue. Also included are compositions comprising a hybrid of decellularized tissue and organotypic organ slice technology. Intact mammalian hearts are precision cut to obtain thin slices in a range of thicknesses, decellularized, and seeded with various mammalian cells which can be from a variety of sources. Methods of investigation of many diseases and methods of use of these compositions for screening compounds for therapeutic purposes are also provided. | 2017-06-22 |
20170173216 | COLLAGEN SCAFFOLDS, MEDICAL IMPLANTS WITH SAME AND METHODS OF USE - The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor. | 2017-06-22 |
20170173217 | Methods for Preparation of a Terminally Sterilized Hydrogel Derived from Extracellular Matrix - Provided are methods for preparing sterilized, gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth substrates. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient. | 2017-06-22 |
20170173218 | ACTIVATION OF ANTIMICROBIAL AGENTS - Post-operative infection in joint prostheses is a problem due to adverse consequences such as surgical debridement or implant removal. Embodiments create a coating that can be powered to release microbicidal agents to both ensure the prevention of infections, and avoid the development of antibiotic resistance. Silver ions have been well established for antimicrobial characteristics, and thus make an advantageous implant coating. Reverse electrolysis allows the ions to be released for a sustained period of time, and then collected back onto to the implant to avoid silver poisoning. A wireless reverse electrolysis system releases a sufficient amount of silver ions to break down biofilm surrounding a joint implant. By applying a modulated current waveform that has a net negative value to a conducting copper strip, the mirror current induced on the silver coating surface has a net positive flow, allowing ions to be released into surrounding tissue. Using this method, an average silver concentration of 32 ppb is created in surrounding medium after 12 hours, sufficient to eradicate bacteria directly around the silver. The ability to wirelessly induce electrolysis of silver ions to kill a significant quantity of bacteria can be used in surgical procedures to avoid post-operative infection in joint prostheses. | 2017-06-22 |
20170173219 | HIGH STRENGTH BIOMEDICAL MATERIALS - High strength biomedical materials and processes for making the same are disclosed. Included in the disclosure are nanoporous hydrophilic solids that can be extruded with a high aspect ratio to make high strength medical catheters and other devices with lubricious and biocompatible surfaces. | 2017-06-22 |
20170173220 | DRUG-ELUTING MEDICAL DEVICE - The present invention relates to a drug-eluting medical device, in particular a balloon for angioplasty catheters with drug elution to prevent the restenosis of the vessel subjected to angioplasty. More particularly, the present invention relates to a catheter balloon completely or partially coated with paclitaxel in hydrated crystalline form or in hydrated solvated crystalline form, having an immediate release and bioavailability of a therapeutically effective amount of paclitaxel at the site of intervention. The balloon can be made of a polyether-polyamide block copolymer, or a polyester amide, or polyamide-12. | 2017-06-22 |
20170173221 | SELF-ASSEMBLING PEPTIDES AS BRONCHIAL OBSTRUCTION AGENTS - Materials and methods for forming a bronchial obstruction are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to provide a bronchial obstruction. | 2017-06-22 |
20170173222 | METHOD OF FABRICATING AN IMPLANTABLE MEDICAL DEVICE COMPRISING A RAPAMYCIN DERIVATIVE - This invention relates to an method of manufacture of an implantable medical device comprising an oxygen-sensitive rapamycin derivative that is protected by addition of an antioxidant during the manufacturing process where the amount of antioxidant added at the outset of the processing is such that when the device is fully fabricated, sterilized and packaged the amount of antioxidant has reduced to a minimal, preferably non-detect, amount. | 2017-06-22 |
20170173223 | BIOLOGICALLY INERT COATING FOR IMPLANTABLE MEDICAL DEVICES - A coating for an implantable medical device includes a poly(monochloro-p-xylylene) coating formed on at least a portion of the implantable medical device, and a layer including at least one of poly(ethylene glycol) and a poly(ethylene glycol) derivative linked to the poly(monochloro-p-xylylene) coating by covalent bonds. | 2017-06-22 |
20170173224 | NOVEL TISSUE SEPARATION BARRIER SYSTEMS AND RELATED METHODS OF USE - The present invention is directed to a tissue separation barrier system for preventing the abnormal union of two or more tissues, as well as related methods of use. These tissue separation barrier systems offer the balance of strength and flexibility to allow the tissues, such as skin, to move in a smooth and natural manner while affording a barrier between two or more tissues. Furthermore, particular embodiments of the present invention include the methods of manufacturing the tissue separation barrier systems of the present invention. | 2017-06-22 |
20170173225 | METHODS FOR COATING IMPLANT SURFACES TO TREAT SURGICAL INFECTIONS - Methods for treating infection at the site of implantation of an orthopedic device in a human or animal subject. The methods include removing the orthopedic device, and implanting a replacement device. A surface of the replacement device is coated with an infection-inhibiting composition having a waxy matrix. The waxy matrix includes an infection-inhibiting material, such as a lipid, an antimicrobial agent, or a combination of a lipid and an antimicrobial agent. | 2017-06-22 |
20170173226 | Immobilization of an Active Agent on a Substrate - The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof. | 2017-06-22 |
20170173227 | SYRINGE FILLING DEVICE FOR FAT TRANSFER - The present disclosure provides systems and methods for transfer of tissue or other materials such as adipose tissue. The systems and methods can include a vessel and a syringe to facilitate transfer of tissue between one or more vessels and tissue implantation devices. | 2017-06-22 |
20170173228 | DEVICE FOR CLEANING A MEDICAL VACUUM PUMP - A device for cleaning a medical vacuum pump, wherein the medical vacuum pump has a suction connector and an air removal opening, which are connected to each other in a fluid-tight manner. The device has a rinsing agent delivery line, connectable to at least one rinsing agent container and having a first port for connection to the suction connector, and a suction line having a second port for connection to the air removal opening and having a vacuum port for connection to a suction source. A rinsing agent can be sucked from the rinsing agent container through the delivery line and via the first port into the medical vacuum pump and from there via the second port through the suction line into an outflow. This device permits simple and rapid cleaning of a vacuum path of medical vacuum pumps. | 2017-06-22 |
20170173229 | Interfaces, Systems, And Methods For Use In Reduced Pressure Tissue Treatment - Systems and devices for treating a tissue site may include an interface adapted to provide a reduced pressure to a dressing. The interface may include a positive-pressure channel for delivering a positive pressure from a positive-pressure port to a positive pressure outlet. The positive-pressure channel may include a constricted portion configured to provide a pressure drop. The interface may additionally include a reduced-pressure channel adapted to deliver reduced pressure to the dressing that substantially corresponds to the pressure drop. The reduced-pressure channel may be fluidly coupled between the positive pressure channel and a side of the interface body adapted to face the dressing. Other systems and devices are disclosed. | 2017-06-22 |
20170173230 | WOUND THERAPY - A wound drain includes a drain tube configured to drain fluid from an interior cavity of a wound, a fluid wicking bandage configured to wick fluid from a surface of the wound, and a suction flange configured to pull fluid from the drain tube and the fluid wicking bandage into a suction flange tube. The suction flange tube is configured to be connected to a vacuum source for draining fluid from the wound. | 2017-06-22 |
20170173231 | ADSORBENT FOR REMOVING HISTONE AND PURIFICATION DEVICE FOR LIQUID DERIVED FROM LIVING ORGANISM - Provided is an adsorbent for removing histones from a liquid derived from a living-organism, including a water-insoluble carrier and a biocompatible polymer. The carrier has activated carbon, a polyester, a polysulfone, or a cationic functional group. Also provided is a device for purifying a liquid derived from a living-organism to remove histones from a liquid derived from a living-organism, which has a housing equipped with an inlet and an outlet for the liquid derived from the living-organism and the above-described adsorbent housed in the housing. The liquid derived from the living-organism is moved through the housing of device for purifying the liquid derived from the living-organism to remove histones from the liquid derived from the living-organism. | 2017-06-22 |
20170173232 | BREAST PUMP SYSTEM AND METHODS - Systems and methods for pumping milk from a breast, wherein the milk is expressed from the breast under suction and milk is expulsed from the pumping mechanism to a collection container under positive pressure. | 2017-06-22 |
20170173233 | SUCTION DEVICE - A breast pump ( | 2017-06-22 |
20170173234 | Suction Pump with a Safety Valve - A suction pump, in particular a breast pump, comprises a bleed valve with a bleed opening, a bleed body which seals the bleed opening and an operating means for operating the bleed body. The bleed body may be operated such that upon opening the valve initially only a partial region of the bleed opening is released and subsequently a greater part thereof or the whole bleed opening is released. The suction pump provides a large functionality with the smallest size and, furthermore, is cheap to produce and easily assembled. | 2017-06-22 |
20170173235 | METHOD, APPARATUS, AND SYSTEM FOR EXPRESSION AND QUANTIFICATION OF HUMAN BREAST MILK - Disclosed herein are devices, systems, and methods for the expression and collection of breast milk. A device in accordance with embodiments comprises an actuatable assembly and a breast interface configured to engage a breast and fluidly seal thereagainst. The breast interface comprises a movable member disposed within at least a portion of the breast interface. The device further comprises a tensile element operatively coupling the actuatable assembly to the movable member. Actuation of the actuatable assembly applies a tensile force to the tensile element, and the tensile element transmits the tensile force to the movable member to move the movable member away from the breast, thereby applying negative pressure to the breast to express milk therefrom. | 2017-06-22 |
20170173236 | HOLLOW PLUG - A mounting element defining a bore, the mounting element being configured to mount to an exterior surface of an organ of a patient. A one way valve sized to be received and retained within the bore of the mounting element is included, the one way valve having an open position and a closed position. The one way valve substantially occludes the bore when the valve is in the closed position. The one way valve is biased in the closed position. A plug having a lumen extending there through is included, the plug being configured to be releasably inserted through at least a portion of the one way valve. The plug is configured to transition the one way valve from the closed position to the open position and to maintain the one way valve in the open position when the plug is inserted within the bore. | 2017-06-22 |
20170173237 | CATHETER - The invention relates to a catheter for the directional conductance of a body fluid, particularly blood. The catheter includes a line segment which has a film tube defining an inner volume. A first port connects the inner volume to an external volume and a second port, arranged distally from the first port, connects the inner volume with the external volume. During operation of the catheter, the body fluid is conducted in the inner volume directionally between the first and second ports. The line segment includes a reinforcement running in the interior of the film tube. The film tube has a foldable section, a connecting region whereat the film tube is connected to the reinforcement, and a stabilized section having a structured profile. | 2017-06-22 |
20170173238 | IMPLANTABLE MECHANICAL CIRCULATORY SUPPORT DEVICES - A mechanical circulatory support device. The mechanical circulatory support device includes an inner casing defining a fluid flow path, the fluid flow path defines a longitudinal axis. A rotor is mounted within the fluid flow path and configured to rotate about the longitudinal axis. A housing is included, the inner casing and the rotor being substantially disposed within the housing. The housing having a cross-sectional shape in a plane transverse to the longitudinal axis which decreases in thickness extending from a medial position to opposite lateral positions. | 2017-06-22 |
20170173239 | SYSTEMS FOR UPGRADING VENTRICLE ASSIST DEVICES - Systems and devices for an updatable blood pump are disclosed herein. The blood pump can be part of a mechanical circulatory support system that can include a system controller and the blood pump. The blood pump can include a rotary motor and a control unit that can communicate with the system controller. The system controller can initiate the update process and can provide the update to the blood pump. Upon initiation of the update process, the control unit can stop the rotary motor. While the rotary motor is stopped, the blood pump can be updated. At the completion of the update, the rotary pump can be restarted. | 2017-06-22 |
20170173240 | AXIAL FLOW IMPLANTABLE MECHANICAL CIRCULATORY SUPPORT DEVICES WITH OUTLET VOLUTE - A mechanical circulatory support device includes an inner housing having an inlet end, an outlet end, and a flow path there between. The flow path defines a longitudinal axis. A volute downstream of the outlet end has an outlet port. A rotor mounted within the inner housing upstream of the volute and configured to rotate about the longitudinal axis is included. The volute includes an inner surface having a minimum radius immediately adjacent the rotor and a maximum radius at the outlet port that is larger than the minimum radius. | 2017-06-22 |
20170173241 | IMPELLER FOR AXIAL FLOW PUMP - A rotor for an axial-flow blood pump has blades projecting outwardly from a hub and channels between the blades. The blades incorporate hydrodynamic bearing surfaces capable of suspending the rotor during operation. The rotor has a configuration which provides superior pumping action and reduced shear of blood passing through the pump. The forwardly facing pressure surfaces of the blades may include outflow corner surface at their downstream ends. The outflow corner surfaces desirably slope rearwardly and intersect the rearwardly-facing suction surfaces of the blades at outflow ends of the blades. | 2017-06-22 |
20170173242 | Modular Implantable Ventricular Assist Device - The invention features modular implantable ventricular assist devices configured to be, at least in part, assembled within a patient. The devices generally include a pump assembly and an expandable frame. The frame is configured to engage tissue of a patient when implanted. The pump assembly is configured to be operably coupled to the frame when the frame is implanted and in the expanded configuration. | 2017-06-22 |
20170173243 | EXTRACORPOREAL CIRCUIT BLOOD CHAMBER HAVING AN INTEGRATED DEAERATION DEVICE - A deaeration device includes a vent structure with a porous material capable of swelling when moistened such that the vent structure can inhibit liquid from escaping while allowing for the removal of gases from liquids. The deaeration device is integrated into a blood chamber of an extracorporeal circuit. The blood chamber may further include sensor components for actively performing measurements on the blood while the deaeration device passively removes air from the blood. In an embodiment, the blood chamber may be an optical blood chamber including an optical measurement sensor that performs measurements used in a determination of a hematocrit level in the blood. | 2017-06-22 |
20170173244 | ARTIFICIAL LUNG AND ARTIFICIAL HEART-LUNG CIRCUIT DEVICE - An artificial lung has a gas exchanger portion with an external circulation-type gas exchanging hollow fiber membrane bundle and a heat exchanger portion with a heat exchanging element. Various design parameters of the gas exchanger and heat exchanger portions are configured to obtain a predetermined performance factor. in one embodiment, the design parameters are adjusted so that when a gas exchange performance, a heat exchange performance coefficient, a blood filling amount, and a blood side pressure loss are measured, they result in a performance factor between 1.5 and 2.5, wherein the performance factor is defined as (gas exchange performance×heat exchange performance coefficient)/(blood filling amount×blood side pressure loss). | 2017-06-22 |
20170173245 | ARTIFICIAL LUNG AND ARTIFICIAL HEART-LUNG CIRCUIT DEVICE - An artificial lung has a gas exchanger portion with an external circulation-type gas exchanging hollow fiber membrane bundle and a heat exchanger portion with a heat exchanging element. Various design parameters of the gas exchanger and heat exchanger portions are configured to obtain a predetermined performance factor. In one embodiment, the design parameters are adjusted so that when a heat exchange performance coefficient of the artificial lung, a blood filling amount of the artificial lung, and a blood side pressure loss of the artificial lung are measured, they result in a performance factor equal to or greater than 1.5, wherein the performance factor is defined as heat exchange performance coefficient/(blood filling amount×blood side pressure loss). | 2017-06-22 |
20170173246 | Extracorporeal Fluidic Device for Collecting Circulating Tumor Cells and Method of Use Thereof - A device can be used to retain circulating tumor cells (CTCs). The device can include a cross-flow module with a retentate channel and a permeate channel. A filter in the cross-flow module can separate the retentate channel from the permeate channel. The filter can be constructed such that CTCs are retained in the retentate channel while other cells can pass through the filter into the permeate channel. A recirculation channel can direct a flow from an outlet of the retentate channel back to an inlet of the retentate channel to thereby concentrate CTCs in the retentate flow. | 2017-06-22 |
20170173247 | METHODS AND SYSTEMS FOR THE DELIVERY OF DISSOLVED GASES AND DE-GASSING MEDICAL FLUID LINES - A method and system for infusing medical liquid with gasses, the system comprising a gas source, a vacuum pump, a temperature-controlled container including a fluid reservoir coupled to the gas source and the vacuum pump, a heating and cooling system, and a sonicator, and a controller configured to de-gas a liquid in the fluid reservoir by activating the vacuum pump, re-gas the liquid in the fluid reservoir by releasing gas from the gas source to the fluid reservoir via a first fluid line, and deliver the re-gassed liquid from the fluid reservoir to a catheter via a second fluid line. | 2017-06-22 |
20170173248 | System and Method for Controlling Venous Air Recovery in a Portable Dialysis System - The present specification discloses a portable dialysis system comprising a mechanism that allows the user to accurately position an air bubble in a venous line, so that it can be safely removed. When an air bubble is detected, the system automatically runs the blood pump in a direction such that the air bubble is placed close to the extraction point on the venous line, from where it can safely be removed using a needleless syringe. | 2017-06-22 |
20170173249 | BLOOD PURIFICATION APPARATUS - A blood purification apparatus that is capable of performing a liquid spill prevention operation and uniformizing the amount of air introduced through an opened portion. The blood purification apparatus includes a dialysate introduction line that allows dialysate to be introduced into a dialyzer; a dialysate discharge line that allows the dialysate to be discharged from the dialyzer; coupling tools that allow free switching between a connected state which causes a closed circuit, and an opened state which causes the closed circuit to be opened to form an opened portion; and a control means that performs a liquid spill prevention operation in which external air is introduced through the opened portion. An air detection means, by which air introduced through the opened portion is detectable, is provided in the vicinity of the coupling tools, and the control means stops the liquid spill prevention operation when air is detected by the air detection means. | 2017-06-22 |
20170173250 | METHOD OF REMOVING BLOOD FROM AN EXTRACORPOREAL BLOOD CIRCUIT, TREATMENT APPARATUS, AND TUBE SYSTEM - The present invention relates to a method of removing blood from an extracorporeal blood circuit following termination of a blood treatment session, wherein blood is concurrently removed both from an arterial conduit portion and from a venous conduit portion of the extracorporeal blood circuit. It further relates to a method for recognizing and/or eliminating air inclusions in or from an extracorporeal blood circuit and a treatment apparatus as well as a tube system. | 2017-06-22 |
20170173251 | Modular Blood Treatment Systems, Units, and Methods - A portable adapter is provided that can include a closure system configured to control the flow of blood and/or dialysate between the adapter and a blood treatment apparatus. Modular systems are also provided that include the portable adapter engaged with various units such as a portable blood processing module, a non-portable base module, and/or a remote module. Methods of conducting blood treatments such as blood circulation, hemodialysis, and hemofiltration, hemodiafiltration, using the modular systems are also provided. The systems, units, and methods enable the engagement and disengagement of the adapter from the various units to conduct, interrupt, and resume blood treatments without disconnecting the adapter from the vasculature of a patient. Modular systems including interchangeable portable and base modules configured for various blood treatments are also provided that can be engaged and disengaged with each other without disconnecting the portable module from the vasculature of a patient. | 2017-06-22 |
20170173252 | ARTERIOVENOUS GRAFT FOR HEMODIALYSIS WITH PUNCTURE-RESISTANT POSTERIOR AND SIDE WALLS - An arteriovenous dialysis access graft configured to be implanted in a subject includes: at least one flexible conduit having first and second end portions, wherein the first end portion is configured to connect to an artery of the subject and the second end portion is configured to connect to a vein of the subject such that blood flows through the at least one conduit; and at least one cannulation chamber positioned between the first end portion and the second end portion of the at least one conduit. The chamber includes: an elongated housing having an inlet and an outlet, a posterior wall, a pair of sidewalls, and an open anterior portion defining a cannulation port; and a self-sealing material extending across the cannulation port. The posterior wall and the sidewalls of the housing are formed of a substantially rigid material. | 2017-06-22 |